Biosimilars Immunization Mayo Clinic 
Pharmaceutical Technology
MAY 19, 2023
The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition.
Pharmacy Times
JUNE 9, 2025
Mayo Clinic. Akkooi A, Mandala M, Kicinski M, Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation. J Clin Oncol. 43, 2025 (suppl 17; abstr LBA9500). doi:10.1200/JCO.2025.43.17_suppl.LBA9500.
Pharmacy Times
JUNE 9, 2025
Tichy, PharmD, MBA, vice chair of pharmacy formulary for Mayo Clinic, explained. Still, confusion remains over the role of pharmacy and therapeutics (P&T) committees in this process. This governance issue is a very hot topic,” Eric M.
Expert insights. Personalized for you.
105 
Let's personalize your content